Aldeyra Therapeutics Inc (OQ:ALDX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 131 HARTWELL AVENUE, SUITE 320
LEXINGTON MA 02421
Tel: 1-917-6182651
Website: https://www.aldeyra.com
IR: See website
<
Key People
Todd C. Brady
President, Chief Executive Officer, Director
Bruce Greenberg
Senior Vice President - Finance, Interim Chief Financial Officer
Stephen Machatha
Chief Development Officer
Business Overview
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Financial Overview
For the fiscal year ended 31 December 2023, Aldeyra Therapeutics Inc revenues was not reported. Net loss decreased 39% to $37.5M. Lower net loss reflects Research and development decrease of 39% to $26.4M (expense), Interest income increase from $2.3M to $7.3M (income), General and administrative expenses decrease of 36% to $2.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.06 to -$0.64.
Employees: 10 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $103.78M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$42.53M as of Dec 31, 2023
Net annual income (TTM): -$37.54M as of Dec 31, 2023
Free cash flow (TTM): -$30.33M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 58,895,768 as of Mar 5, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.